Medical Therapy to Prevent or Slow Progression of Aortic Stenosis: Current Evidence and Future Directions.

Degenerative aortic stenosis is a growing clinical problem owing to the high incidence in an aging population and its significant morbidity and mortality. Currently, aortic valve replacement remains the only treatment. Despite promising observational data, pharmacological management to slow or halt progression of aortic stenosis has remained elusive. Nevertheless, with a greater understanding of the mechanisms which underpin aortic stenosis, research has begun to explore novel treatment strategies. This review will explore the historical agents used to manage aortic stenosis and the emerging agents that are currently under investigation.

[1]  D. Playford,et al.  Counting the cost of premature mortality with progressively worse aortic stenosis in Australia: a clinical cohort study , 2022, The Lancet. Healthy longevity.

[2]  D. Playford,et al.  Increasing risk of mortality across the spectrum of aortic stenosis is independent of comorbidity & treatment: An international, parallel cohort study of 248,464 patients , 2022, PloS one.

[3]  J. Lindholt,et al.  Vitamin K2 and D in Patients With Aortic Valve Calcification: A Randomized Double-Blinded Clinical Trial , 2022, Circulation.

[4]  C. Bauters,et al.  Association of Mortality With Aortic Stenosis Severity in Outpatients: Results From the VALVENOR Study. , 2021, JAMA cardiology.

[5]  B. Prendergast,et al.  2021 ESC/EACTS Guidelines for the management of valvular heart disease. , 2021, European heart journal.

[6]  S. Stewart,et al.  Incident aortic stenosis in 49 449 men and 42 229 women investigated with routine echocardiography , 2021, Heart.

[7]  E. V. van Beek,et al.  Effect of Denosumab or Alendronic Acid on the Progression of Aortic Stenosis , 2021, Circulation.

[8]  M. Mack,et al.  2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2020, Circulation.

[9]  M. Mack,et al.  2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2020, Circulation.

[10]  J. Moon,et al.  Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis , 2020, Journal of the American College of Cardiology.

[11]  G. Cho,et al.  Dipeptidyl peptidase-4 inhibition to prevent progression of calcific aortic stenosis , 2020, Heart.

[12]  G. Hankey,et al.  Colchicine in Patients with Chronic Coronary Disease. , 2020, The New England journal of medicine.

[13]  G. Alishiri,et al.  Alendronate slows down aortic stenosis progression in osteoporotic patients: An observational prospective study , 2020, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.

[14]  N. Weissman,et al.  Left Ventricular Hypertrophy and Clinical Outcomes Over 5 Years After TAVR: An Analysis of the PARTNER Trials and Registries. , 2020, JACC. Cardiovascular interventions.

[15]  N. Weissman,et al.  Regression of Left Ventricular Mass After Transcatheter Aortic Valve Replacement: The PARTNER Trials and Registries. , 2020, Journal of the American College of Cardiology.

[16]  J. Hallas,et al.  Association of aortic valve calcification and vitamin K antagonist treatment. , 2020, European heart journal cardiovascular Imaging.

[17]  J. Moon,et al.  Prevalence and outcome of dual aortic stenosis and cardiac amyloid pathology in patients referred for transcatheter aortic valve implantation , 2020, European heart journal.

[18]  Lawrence A Leiter,et al.  Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. , 2020, The New England journal of medicine.

[19]  A. Masri,et al.  Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis , 2020, European journal of heart failure.

[20]  M. Dweck,et al.  Pathophysiology of Aortic Stenosis and Future Perspectives for Medical Therapy. , 2020, Cardiology clinics.

[21]  Deepak L. Bhatt,et al.  Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. , 2020, Journal of the American College of Cardiology.

[22]  J. Tardif,et al.  Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. , 2020, The New England journal of medicine.

[23]  J. Witztum,et al.  Statin therapy increases lipoprotein(a) levels. , 2020, European heart journal.

[24]  Christopher N. Foley,et al.  Genetic Determinants of Lipids and Cardiovascular Disease Outcomes , 2019, Circulation. Genomic and precision medicine.

[25]  R. Diaz,et al.  Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. , 2019, The New England journal of medicine.

[26]  G. Tell,et al.  Association of Low-Density Lipoprotein Cholesterol With Risk of Aortic Valve Stenosis in Familial Hypercholesterolemia. , 2019, JAMA cardiology.

[27]  S. Stewart,et al.  Poor Long-term Survival in Patients with Moderate Aortic Stenosis. , 2019, Journal of the American College of Cardiology.

[28]  M. Dweck,et al.  Why and How to Measure Aortic Valve Calcification in Patients With Aortic Stenosis. , 2019, JACC. Cardiovascular imaging.

[29]  M. Koschinsky,et al.  Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association. , 2022, Journal of clinical lipidology.

[30]  Michael A. Raddatz,et al.  Celecoxib Is Associated With Dystrophic Calcification and Aortic Valve Stenosis , 2019, JACC. Basic to translational science.

[31]  M. Dweck,et al.  The Role of Imaging in Measuring Disease Progression and Assessing Novel Therapies in Aortic Stenosis , 2019, JACC. Cardiovascular imaging.

[32]  A. Keech,et al.  Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial , 2019, Circulation.

[33]  J. Carroll,et al.  Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement , 2018, JAMA.

[34]  P. Pibarot,et al.  Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels: Secondary Analysis of a Randomized Clinical Trial , 2018, JAMA cardiology.

[35]  W. Kernan,et al.  Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2018, Diabetologia.

[36]  Irl B Hirsch,et al.  AACE/ACE Consensus Statement CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2018 EXECUTIVE SUMMARY , 2018 .

[37]  P. Kadowitz,et al.  The Nitric Oxide Pathway in Pulmonary Vascular Disease. , 2017, The American journal of cardiology.

[38]  M. Leon,et al.  Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement , 2017, European heart journal.

[39]  S. Saito,et al.  Renin–angiotensin system blockade therapy after transcatheter aortic valve implantation , 2017, Heart.

[40]  J. Sörensen,et al.  Metoprolol Reduces Hemodynamic and Metabolic Overload in Asymptomatic Aortic Valve Stenosis Patients: A Randomized Trial , 2017, Circulation. Cardiovascular imaging.

[41]  G. Sullivan,et al.  Valve Interstitial Cells: The Key to Understanding the Pathophysiology of Heart Valve Calcification , 2017, Journal of the American Heart Association.

[42]  L. Schurgers,et al.  Slower Progress of Aortic Valve Calcification With Vitamin K Supplementation: Results From a Prospective Interventional Proof-of-Concept Study. , 2017, Circulation.

[43]  Ki-Up Lee,et al.  Dipeptidyl Peptidase-4 Induces Aortic Valve Calcification by Inhibiting Insulin-Like Growth Factor-1 Signaling in Valvular Interstitial Cells , 2017, Circulation.

[44]  V. Salomaa,et al.  Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium , 2017, European heart journal.

[45]  T. Tamura,et al.  Dietary soy and natto intake and cardiovascular disease mortality in Japanese adults: the Takayama study. , 2017, The American journal of clinical nutrition.

[46]  Y. Bossé,et al.  Systolic hypertension and progression of aortic valve calcification in patients with aortic stenosis: results from the PROGRESSA study , 2017, European heart journal cardiovascular Imaging.

[47]  Gonçalo R. Abecasis,et al.  Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels. , 2016, Journal of the American College of Cardiology.

[48]  M. Leon,et al.  Medical Treatment of Aortic Stenosis , 2016, Circulation.

[49]  P. Libby,et al.  Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. , 2016, The New England journal of medicine.

[50]  Ž. Reiner,et al.  Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials. , 2016, Metabolism: clinical and experimental.

[51]  C. R. Macedo,et al.  Statins for aortic valve stenosis. , 2016, The Cochrane database of systematic reviews.

[52]  B. Nordestgaard,et al.  PCSK9 R46L Loss-of-Function Mutation Reduces Lipoprotein(a), LDL Cholesterol, and Risk of Aortic Valve Stenosis. , 2016, The Journal of clinical endocrinology and metabolism.

[53]  J. Tardif,et al.  Resting heart rate as a predictor of aortic valve stenosis progression. , 2016, International journal of cardiology.

[54]  W. C. O'Neill,et al.  Increased Peripheral Arterial Calcification in Patients Receiving Warfarin , 2016, Journal of the American Heart Association.

[55]  M. Weyant,et al.  Matrix Gla protein regulates calcification of the aortic valve. , 2015, The Journal of surgical research.

[56]  G. Cioffi,et al.  See Clinical Perspective See Editorial by Barasch and Reichek , 2022 .

[57]  J. Zhan,et al.  The protective effect of GLP-1 analogue in arterial calcification through attenuating osteoblastic differentiation of human VSMCs. , 2015, International journal of cardiology.

[58]  B. Prendergast,et al.  A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial) , 2015, European heart journal cardiovascular Imaging.

[59]  P. Okin,et al.  Resting heart rate and risk of adverse cardiovascular outcomes in asymptomatic aortic stenosis: the SEAS study. , 2015, International journal of cardiology.

[60]  Michael J Blaha,et al.  Relation of resting heart rate to risk for all-cause mortality by gender after considering exercise capacity (the Henry Ford exercise testing project). , 2014, The American journal of cardiology.

[61]  P. Pibarot,et al.  Left Ventricular Remodeling in Aortic Stenosis , 2014 .

[62]  L. Køber,et al.  Renin-angiotensin system inhibition is not associated with increased sudden cardiac death, cardiovascular mortality or all-cause mortality in patients with aortic stenosis. , 2014, International journal of cardiology.

[63]  Susan Cheng,et al.  Long‐term Cardiovascular Risks Associated With an Elevated Heart Rate: The Framingham Heart Study , 2014, Journal of the American Heart Association.

[64]  P. Barter,et al.  Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL). , 2014, The American journal of cardiology.

[65]  Y. Bossé,et al.  Elevated expression of lipoprotein-associated phospholipase A2 in calcific aortic valve disease: implications for valve mineralization. , 2014, Journal of the American College of Cardiology.

[66]  C. Hassager,et al.  Short-term hemodynamic effect of angiotensin-converting enzyme inhibition in patients with severe aortic stenosis: a placebo-controlled, randomized study. , 2014, American heart journal.

[67]  M. Sandhu,et al.  Lipoprotein(a) levels, genotype and incident aortic stenosis: a prospective Mendelian randomization study and replication in a case-control cohort , 2013 .

[68]  B. Nordestgaard,et al.  Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. , 2013, Journal of the American College of Cardiology.

[69]  S. Body,et al.  Calcific aortic valve disease: a consensus summary from the Alliance of Investigators on Calcific Aortic Valve Disease. , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[70]  R. Bonow,et al.  Current management of calcific aortic stenosis. , 2013, Circulation research.

[71]  B. Lilly,et al.  Endothelial nitric oxide signaling regulates Notch1 in aortic valve disease. , 2013, Journal of molecular and cellular cardiology.

[72]  P. Kovanen,et al.  Modified Lipoprotein-Derived Lipid Particles Accumulate in Human Stenotic Aortic Valves , 2013, PloS one.

[73]  R. Brooks,et al.  Osteoprotegerin Inhibits Aortic Valve Calcification and Preserves Valve Function in Hypercholesterolemic Mice , 2013, PloS one.

[74]  J. Uitto,et al.  Vitamin K-dependent carboxylation of matrix Gla-protein: a crucial switch to control ectopic mineralization. , 2013, Trends in molecular medicine.

[75]  A. Luttun,et al.  Increased Cardiac Myocyte PDE5 Levels in Human and Murine Pressure Overload Hypertrophy Contribute to Adverse LV Remodeling , 2013, PloS one.

[76]  Joseph Chen,et al.  Cadherin-11 Regulates Cell–Cell Tension Necessary for Calcific Nodule Formation by Valvular Myofibroblasts , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[77]  R. Sacco,et al.  Higher Ambulatory Blood Pressure Is Associated With Aortic Valve Calcification in the Elderly: A Population-Based Study , 2013, Hypertension.

[78]  J. Peteiro,et al.  Association of Left Ventricular Mass with All-Cause Mortality, Myocardial Infarction and Stroke , 2012, PloS one.

[79]  Oakland J. Peters,et al.  Predicting new indications for approved drugs using a proteochemometric method. , 2012, Journal of medicinal chemistry.

[80]  J. Després,et al.  Impact of metabolic syndrome on progression of aortic stenosis: influence of age and statin therapy. , 2012, Journal of the American College of Cardiology.

[81]  E. Staal,et al.  Hypertension in Aortic Stenosis: Implications for Left Ventricular Structure and Cardiovascular Events , 2012, Hypertension.

[82]  B. Gage,et al.  Effects of Phosphodiesterase Type 5 Inhibition on Systemic and Pulmonary Hemodynamics and Ventricular Function in Patients With Severe Symptomatic Aortic Stenosis , 2012, Circulation.

[83]  J. J. Rivera,et al.  The relationship between resting heart rate and incidence and progression of coronary artery calcification: the Multi-Ethnic Study of Atherosclerosis (MESA). , 2012, Atherosclerosis.

[84]  J. Després,et al.  Angiotensin receptor blockers are associated with a lower remodelling score of stenotic aortic valves , 2011, European journal of clinical investigation.

[85]  K. J. Grande-Allen,et al.  Calcific Aortic Valve Disease : Not Simply a Degenerative Process A Review and Agenda for Research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group , 2012 .

[86]  C. Lang,et al.  Impact of renin-angiotensin system blockade therapy on outcome in aortic stenosis. , 2011, Journal of the American College of Cardiology.

[87]  B. Mulder,et al.  Effects of rosuvastatin on progression of stenosis in adult patients with congenital aortic stenosis (PROCAS Trial). , 2011, The American journal of cardiology.

[88]  Yuan Zhang,et al.  Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations , 2011, British journal of pharmacology.

[89]  E. Aikawa,et al.  Cardiovascular calcification: an inflammatory disease. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[90]  K. Linhartová,et al.  Bisphosphonates in Calcific Aortic Stenosis: Association with Slower Progression in Mild Disease – A Pilot Retrospective Study , 2010, Cardiology.

[91]  R. Kronmal,et al.  Bisphosphonate Use and Prevalence of Valvular and Vascular Calcification in Women MESA (The Multi-Ethnic Study of Atherosclerosis). , 2010, Journal of the American College of Cardiology.

[92]  J. Bauersachs,et al.  Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure. , 2010, Pharmacological research.

[93]  F. Salvi,et al.  Transthyretin-related amyloidoses and the heart: a clinical overview , 2010, Nature Reviews Cardiology.

[94]  S. Siu,et al.  Bicuspid aortic valve disease. , 2010, Journal of the American College of Cardiology.

[95]  Erkki Vartiainen,et al.  Elevated resting heart rate is an independent risk factor for cardiovascular disease in healthy men and women. , 2010, American heart journal.

[96]  R. Kronmal,et al.  Incidence and progression of aortic valve calcium in the Multi-ethnic Study of Atherosclerosis (MESA). , 2010, The American journal of cardiology.

[97]  K. Teo,et al.  Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis: Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial , 2010, Circulation.

[98]  Børge G Nordestgaard,et al.  Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. , 2009, JAMA.

[99]  Eugenio Cervesato,et al.  Hydroxymethylglutaryl coenzyme-a reductase inhibitors delay the progression of rheumatic aortic valve stenosis a long-term echocardiographic study. , 2009, Journal of the American College of Cardiology.

[100]  Robert David,et al.  Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. , 2009, Cell stem cell.

[101]  D. Grobbee,et al.  High dietary menaquinone intake is associated with reduced coronary calcification. , 2009, Atherosclerosis.

[102]  Georgios A. Dalkas,et al.  Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress. , 2008, American journal of physiology. Heart and circulatory physiology.

[103]  J. Chambers,et al.  Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. , 2008, The New England journal of medicine.

[104]  R. Brooks,et al.  Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. , 2008, Journal of the American College of Cardiology.

[105]  B. Psaty,et al.  Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease: the Cardiovascular Health Study. , 2007, Journal of the American College of Cardiology.

[106]  Jean-Claude Tardif,et al.  Resting heart rate in cardiovascular disease. , 2007, Journal of the American College of Cardiology.

[107]  J. Zamorano,et al.  Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. , 2007, Journal of the American College of Cardiology.

[108]  K. Griendling,et al.  Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. , 2007, American journal of physiology. Cell physiology.

[109]  R. Bansal,et al.  Malignant natural history of asymptomatic severe aortic stenosis: benefit of aortic valve replacement. , 2006, The Annals of thoracic surgery.

[110]  Damien Garcia,et al.  Reduced systemic arterial compliance impacts significantly on left ventricular afterload and function in aortic stenosis: implications for diagnosis and treatment. , 2005, Journal of the American College of Cardiology.

[111]  R. Prescott,et al.  A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. , 2005, The New England journal of medicine.

[112]  M. Budoff,et al.  Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. , 2005, Archives of internal medicine.

[113]  D. Kass,et al.  Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy , 2005, Nature Medicine.

[114]  M. Mäyränpää,et al.  Induction of local angiotensin II-producing systems in stenotic aortic valves. , 2004, Journal of the American College of Cardiology.

[115]  A. Hofman,et al.  Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. , 2004, The Journal of nutrition.

[116]  M. Schemper,et al.  Statins but Not Angiotensin-Converting Enzyme Inhibitors Delay Progression of Aortic Stenosis , 2004, Circulation.

[117]  M. McKee,et al.  Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins , 2004, The Journal of cell biology.

[118]  R Alagesan,et al.  Safety and efficacy of angiotensin-converting enzyme inhibitors in symptomatic severe aortic stenosis: Symptomatic Cardiac Obstruction-Pilot Study of Enalapril in Aortic Stenosis (SCOPE-AS). , 2004, American heart journal.

[119]  Frank McCormick,et al.  Notch promotes epithelial-mesenchymal transition during cardiac development and oncogenic transformation. , 2004, Genes & development.

[120]  S. Hagl,et al.  Receptor activator of nuclear factor κB ligand and osteoprotegerin regulate aortic valve calcification , 2004 .

[121]  B. Popescu,et al.  Effect of statins on the progression of bioprosthetic aortic valve degeneration. , 2003, The American journal of cardiology.

[122]  M. Enriquez-Sarano,et al.  Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. , 2002, Journal of the American College of Cardiology.

[123]  M. Budoff,et al.  HMG CoA reductase inhibitor (statin) and aortic valve calcium , 2002, The Lancet.

[124]  M. Lauer,et al.  Effect of Hydroxymethylglutaryl Coenzyme A Reductase Inhibitors on the Progression of Calcific Aortic Stenosis , 2001, Circulation.

[125]  S. Achenbach,et al.  Progression of Aortic Valve Calcification: Association with Coronary Progression of Aortic Valve Calcification Association with Coronary Atherosclerosis and Cardiovascular Risk Factors , 2022 .

[126]  A. Gown,et al.  Characterization of the Early Lesion of ‘Degenerative’ Valvular Aortic Stenosis: Histological and Immunohistochemical Studies , 1994, Circulation.

[127]  K. Watson,et al.  Bone morphogenetic protein expression in human atherosclerotic lesions. , 1993, The Journal of clinical investigation.

[128]  D. Levy,et al.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.

[129]  K. Chandran,et al.  Experimental fluid dynamics of aortic stenosis in a model of the human aorta. , 1989, Clinical physics and physiological measurement : an official journal of the Hospital Physicists' Association, Deutsche Gesellschaft fur Medizinische Physik and the European Federation of Organisations for Medical Physics.

[130]  R. Miller,et al.  Effects of isometric exercise and increased arterial impedance on left ventricular function in severe aortic valvular stenosis. , 1977, British heart journal.

[131]  W. Gaasch,et al.  Left ventricular compliance: mechanisms and clinical implications. , 1976, The American journal of cardiology.